Obsidian Therapeutics eyes IPO after $115M fundraise

After raising $115 million from a handful of high-profile investors, cell and gene therapy startup Obsidian Therapeutics has its sights set on an IPO by early 2023. The company expects to advance its first cancer drug into the clinic in the same timeframe. It also plans to move to Bedford.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news